Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amarin Says REDUCE-IT Results Are Off Limits To Omega-3 Supplement Claims

Related Content

DoJ Maintains Amarin 'Misplaced' Its Omega-3 Unfair Trade Argument

May 07 2018

IoniCell, BiomeBliss, Coromega, Ashwagandha: Health And Wellness New Products

Apr 12 2018

Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement

Mar 14 2016

'That's Huge, Folks': Amarin's Vascepa Cuts CV Risk By 25% On Top Of Statins

Sep 25 2018

Related Companies

Amarin Corp plc

Additional Topics

United States Advertising, Marketing & Sales Dietary Supplements Legal Issues OTC Drugs Consumer Cardiovascular

More from Marketing & Advertising

More from Compliance

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window